Videos

New research links sleep inertia and daytime sleepiness to dangerous falls in older adults—learn which sleep habits may prevent injuries.

Learn more about sleep issues and their relation to Alzheimer disease.

New research links better NREM sleep to slower Alzheimer disease changes: zolpidem restores brain rhythms, cuts amyloid, and boosts memory in mice models.

Explore the intersections of bipolar disorder with clinical trials and AI.

Caplyta boosts antidepressants in MDD, showing 2–4 week response with minimal weight, metabolic, and EPS risks.

Carlos H. Schenck, MD, delivered the keynote address at SLEEP 2026 on REM sleep behavior disorder. Here's what psychiatrists and mental health clinicians need to know.

Delphi panel reveals how NPs and PAs can talk about long-acting injectables earlier in schizophrenia, boosting adherence and cutting relapse.

Let's take a look at the next generation of pharmacotherapies for mood and anxiety disorders.

Alixorexton boosts wakefulness in type 1 narcolepsy, shows cognitive and fatigue gains, and hints at ADHD and neurodegenerative uses.

In the first ever episode of "Psychopharm Today," experts unpack why suicide needs its own research, how to design targeted studies, and what clinicians can do beyond diagnosis to reduce risk.

How AI can aid everyday psychiatry—TRD prediction, suicide risk, and smartphone phenotyping—plus why data quality and workflow still block adoption.

Phase 2 depression trial shows ALTO-203 boosts attention, EEG theta-beta ratio and alertness, pointing to biomarker-guided dosing and precision psychiatry.

How social determinants and care gaps drive schizophrenia relapse—strategies to boost adherence, coordination, and follow-up after hospitalization.

Poorly managed schizophrenia fuels relapse, homelessness and caregiver strain—new data shows most costs are indirect, making prevention and LAIs pivotal.

Poor schizophrenia control drives relapse, homelessness and caregiver strain; data show $367B burden—why relapse prevention and LAIs matter.

Post hoc SUSTAIN-1 data reveal who relapses after stopping intranasal esketamine in TRD—key risk factors guide personalized relapse-prevention plans.

AI analyzes wearable data to reveal objective biomarkers for ADHD and anxiety, enabling passive tracking and earlier psychiatric detection.

Expert analysis compares adjunctive atypical antipsychotics for MDD, highlighting lumatperone’s larger effect and minimal weight gain or akathisia.

Yale psychiatrists test esketamine vs IV ketamine for resistant depression, probing long-term safety, side effects, and misuse in real-world care.

APA’s upcoming DSM shifts from “statistical” to “scientific,” adding dimensional, contextual, and biological factors to modernize diagnosis and address past critiques.

After FDA’s new warning, experts stress controlled data show acetaminophen in pregnancy isn’t tied to autism or ADHD; confounding fuels scares.

New evidence shows CBT timed after ketamine boosts lasting depression relief; Yale tests digital therapy Rejoyn to scale the neuroplasticity window.

APA’s next DSM rebrands and adds context, cross-cutting symptoms, and biomarker-ready science to sharpen diagnoses and personalize psychiatric care.

New analysis finds postpartum depression and postpartum psychosis have distinct underlying biological mechanisms.

Weighing the risks and benefits of stimulants to treat ADHD.

Review the origins and advancements of ECT.

Luvesilocin enters phase 2, hinting at lasting relief after 1–2 doses and a new 5-HT2A model.

Phase 2 data suggest luvesilocin quickly eases postpartum depression with durable remission and minimal breast‑milk transfer, supporting larger trials.

S. Nassir Ghaemi, MD, shares highlights from the ASCP task force consensus on psychiatric polypharmacy, emphasizing monotherapy and diagnostic reassessment.

ASPIRE survey reveals fatigue and cognitive impairment reduce work abilities and quality of life in narcolepsy and idiopathic hypersomnia, exposing unmet needs.